Ascendis Pharma A/S $ASND Shares Acquired by Moore Capital Management LP

Moore Capital Management LP grew its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 38.9% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 125,000 shares of the biotechnology company’s stock after purchasing an additional 35,000 shares during the period. Moore Capital Management LP owned approximately 0.20% of Ascendis Pharma A/S worth $26,655,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also modified their holdings of ASND. Advisory Services Network LLC acquired a new position in shares of Ascendis Pharma A/S in the 3rd quarter valued at $26,000. Arax Advisory Partners lifted its stake in shares of Ascendis Pharma A/S by 212.2% in the 4th quarter. Arax Advisory Partners now owns 153 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 104 shares during the last quarter. Leonteq Securities AG acquired a new position in shares of Ascendis Pharma A/S in the 4th quarter valued at $36,000. Jones Financial Companies Lllp lifted its stake in shares of Ascendis Pharma A/S by 57.2% in the 3rd quarter. Jones Financial Companies Lllp now owns 228 shares of the biotechnology company’s stock valued at $44,000 after purchasing an additional 83 shares during the last quarter. Finally, Global Retirement Partners LLC lifted its stake in shares of Ascendis Pharma A/S by 111.9% in the 4th quarter. Global Retirement Partners LLC now owns 214 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 113 shares during the last quarter.

Ascendis Pharma A/S Price Performance

ASND opened at $231.15 on Thursday. The stock’s 50-day moving average price is $232.16 and its 200 day moving average price is $224.09. Ascendis Pharma A/S has a 12-month low of $160.86 and a 12-month high of $250.74. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. The firm has a market cap of $14.42 billion, a price-to-earnings ratio of 26.66 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million for the quarter, compared to analyst estimates of $362.47 million. As a group, sell-side analysts expect that Ascendis Pharma A/S will post 14.25 earnings per share for the current year.

Insider Activity

In related news, Director Jean Jacques Bienaime purchased 400 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were bought at an average price of $237.80 per share, for a total transaction of $95,120.00. Following the acquisition, the director directly owned 400 shares in the company, valued at $95,120. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Flemming Steen Jensen sold 19,460 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $238.49, for a total value of $4,641,015.40. The disclosure for this sale is available in the SEC filing. 40.00% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have recently commented on the company. Jefferies Financial Group assumed coverage on Ascendis Pharma A/S in a research note on Monday, March 16th. They issued a “buy” rating and a $290.00 price target on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $300.00 price target on shares of Ascendis Pharma A/S in a research note on Monday, March 2nd. Royal Bank Of Canada upped their price target on Ascendis Pharma A/S from $250.00 to $275.00 and gave the company an “outperform” rating in a research note on Monday, March 2nd. Evercore reaffirmed an “outperform” rating and issued a $329.00 price target on shares of Ascendis Pharma A/S in a research note on Friday, May 15th. Finally, Citigroup assumed coverage on Ascendis Pharma A/S in a research note on Monday, May 18th. They issued a “buy” rating and a $355.00 price target on the stock. Two analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has an average rating of “Buy” and an average price target of $295.39.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.